CN101421262A - 作为蛋白激酶抑制剂的化合物和组合物 - Google Patents

作为蛋白激酶抑制剂的化合物和组合物 Download PDF

Info

Publication number
CN101421262A
CN101421262A CNA2007800046499A CN200780004649A CN101421262A CN 101421262 A CN101421262 A CN 101421262A CN A2007800046499 A CNA2007800046499 A CN A2007800046499A CN 200780004649 A CN200780004649 A CN 200780004649A CN 101421262 A CN101421262 A CN 101421262A
Authority
CN
China
Prior art keywords
methyl
amino
phenyl
pyrimidin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800046499A
Other languages
English (en)
Chinese (zh)
Inventor
丁强
任平达
张琼
王霞
沈台辅
P·A·阿尔博格
N·S·格雷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IRM LLC
Original Assignee
IRM LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IRM LLC filed Critical IRM LLC
Publication of CN101421262A publication Critical patent/CN101421262A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
CNA2007800046499A 2006-02-06 2007-02-06 作为蛋白激酶抑制剂的化合物和组合物 Pending CN101421262A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77104506P 2006-02-06 2006-02-06
US60/771,045 2006-02-06

Publications (1)

Publication Number Publication Date
CN101421262A true CN101421262A (zh) 2009-04-29

Family

ID=38255301

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800046499A Pending CN101421262A (zh) 2006-02-06 2007-02-06 作为蛋白激酶抑制剂的化合物和组合物

Country Status (10)

Country Link
US (1) US20090069327A1 (fr)
EP (1) EP1981870A2 (fr)
JP (1) JP2009525978A (fr)
KR (1) KR20080092412A (fr)
CN (1) CN101421262A (fr)
AU (1) AU2007212345A1 (fr)
BR (1) BRPI0707666A2 (fr)
CA (1) CA2637225A1 (fr)
RU (1) RU2008135690A (fr)
WO (1) WO2007092531A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022206939A1 (fr) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 Composé hétérocyclique servant d'inhibiteur de fgfr et son application

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
DK2300013T3 (en) 2008-05-21 2017-12-04 Ariad Pharma Inc PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
UY32582A (es) * 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
WO2012021415A2 (fr) * 2010-08-07 2012-02-16 Research Foundation Of State University Of New York Compositions buccales comprenant un composé de zinc et un agent antimicrobien
ES2562010T3 (es) 2010-12-02 2016-03-02 Medpacto Inc. Derivado de purinilpiridinilamino-2,4-difluorofenilsulfonamida, sal farmacéuticamente aceptable del mismo, método de preparación del mismo y composición farmacéutica con actividad inhibidora contra cinasa Raf, que contiene el mismo como ingrediente activo
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
JP2014517016A (ja) 2011-06-10 2014-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｔｋ阻害活性を有するピリミジンおよびピリミジン化合物の組成物と製造方法
US9061028B2 (en) * 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US11174250B2 (en) 2016-03-01 2021-11-16 Propellon Therapeutics Inc. Substituted carboxamides as inhibitors of WDR5 protein-protein binding
EA038109B1 (ru) 2016-03-01 2021-07-07 Пропеллон Терапьютикс Инк. Ингибиторы связывания белка wdr5 с белками
EP3848370A3 (fr) * 2016-10-14 2021-09-15 Nimbus Lakshmi, Inc. Inhibiteurs de tyk2 et leurs utilisations
CN113164478A (zh) * 2018-09-13 2021-07-23 南加州大学 新型fgfr抑制剂及其用途
JP2022521715A (ja) 2019-02-14 2022-04-12 ブリッドジーン バイオサイエンシズ インコーポレイテッド がん治療のためのｆｇｆｒ阻害剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007507531A (ja) * 2003-09-30 2007-03-29 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
JP5097539B2 (ja) * 2004-05-07 2012-12-12 アムジエン・インコーポレーテツド タンパク質キナーゼ調節剤および使用方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022206939A1 (fr) * 2021-04-03 2022-10-06 海南耀臻生物医药科技有限公司 Composé hétérocyclique servant d'inhibiteur de fgfr et son application

Also Published As

Publication number Publication date
WO2007092531A2 (fr) 2007-08-16
RU2008135690A (ru) 2010-03-20
US20090069327A1 (en) 2009-03-12
KR20080092412A (ko) 2008-10-15
BRPI0707666A2 (pt) 2011-05-10
JP2009525978A (ja) 2009-07-16
CA2637225A1 (fr) 2007-08-16
AU2007212345A1 (en) 2007-08-16
WO2007092531A3 (fr) 2007-10-18
EP1981870A2 (fr) 2008-10-22

Similar Documents

Publication Publication Date Title
CN101421262A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN101296928B (zh) 作为蛋白激酶抑制剂的化合物和组合物
ES2367666T3 (es) Derivados de [4,5']bipirimidinil-6,4'-diamina como inhibidores de proteína quinasa.
CN101213192B (zh) 作为蛋白激酶抑制剂的嘧啶取代的苯并咪唑衍生物
CN102083828B (zh) 作为c-kit和pdgfr激酶抑制剂的杂环化合物和组合物
CN101175753B (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN101720322A (zh) 作为c-kit和pdgfr激酶抑制剂的化合物和组合物
CN1960988B (zh) 作为蛋白激酶抑制剂的化合物和组合物
AU2007317349B2 (en) Compounds and compositions as protein kinase inhibitors
CN101687853A (zh) 作为c-kit和pdgfr激酶抑制剂的嘧啶衍生物和组合物
CN101522661A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN101291938A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN101500574A (zh) 用作蛋白激酶抑制剂的化合物和组合物
CN101687821A (zh) 蛋白激酶抑制剂及其使用方法
CN101300234A (zh) 蛋白激酶抑制剂
CN101707863A (zh) 蛋白激酶抑制剂及其使用方法
CN101687854A (zh) 作为c-kit和pdgfr激酶抑制剂的化合物和组合物
CN101437822A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN101282975A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN101784530A (zh) 作为激酶抑制剂的5-(4-(卤代烷氧基)苯基)嘧啶-2-胺化合物和组合物
CN101273023A (zh) 作为蛋白激酶抑制剂的5-取代的噻唑-2-基氨基化合物和组合物
MX2008009925A (en) Compounds and compositions as protein kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090429